---
title: "China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600750.SH.md"
symbol: "600750.SH"
name: "China Resources Jiangzhong Pharmaceutical Co.,Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-20T09:11:35.818Z"
locales:
  - [en](https://longbridge.com/en/quote/600750.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600750.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600750.SH.md)
---

# China Resources Jiangzhong Pharmaceutical Co.,Ltd (600750.SH)

## Company Overview

China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsules, bezoar and snake gallbladder fritillaria liquid, and compound gold melon seed. It also provides health consumer and other products, such as nourishing, tonics, rehabilitation nutrition, gastrointestinal health, and liver health products. In addition, the company offers prescription drugs comprising traditional Chinese medicine products, which includes Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules; chemical medicine products, such as lumbrokinase enteric-coated capsules, Rabeprazole sodium enteric-coated tablets, chloroprocaine hydrochloride, etc.; and medicinal materials which includes codonopsis pilosula.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.crjz.com](https://www.crjz.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.40)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 87 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.31% |  |
| Net Profit YoY | 13.15% |  |
| P/B Ratio | 3.36 |  |
| Dividend Ratio | 5.26% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14517759959.25 |  |
| Revenue | 4078815141.37 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 21.50% | A |
| Profit Margin | 22.35% | A |
| Gross Margin | 68.13% | A |
| Revenue YoY | -6.31% | D |
| Net Profit YoY | 13.15% | C |
| Total Assets YoY | 7.11% | B |
| Net Assets YoY | 5.06% | C |
| Cash Flow Margin | 90.79% | C |
| OCF YoY | -6.31% | D |
| Turnover | 0.59 | B |
| Gearing Ratio | 29.88% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - China Resources Jiangzhong Pharmaceutical Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.31%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "13.15%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.36",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "5.26%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14517759959.25",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4078815141.37",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "21.50%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "22.35%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "68.13%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.31%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "13.15%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.11%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.06%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "90.79%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-6.31%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.59",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "29.88%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.93 | 20/215 | 18.79 | 17.48 | 16.95 |
| PB | 3.36 | 151/215 | 4.12 | 3.58 | 3.45 |
| PS (TTM) | 3.56 | 96/215 | 3.74 | 3.36 | 3.22 |
| Dividend Yield | 5.26% | 7/215 | 5.47% | 5.24% | 4.80% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T16:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 2 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.88 |
| Highest Target | 31.50 |
| Lowest Target | 28.63 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600750.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600750.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600750.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600750.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**